Research graph
References from Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access. Local targets link to admitted publications; unresolved targets remain external evidence.
Intranasal delivery: an attractive route for administration of nanoparticles to the brain
10.3389/fphar.2022.974666 · 2022 · External reference
Hyaluronidase use in aesthetic medicine: formulations, safety, and clinical practice
10.3390/jcm15010279 · 2025 · External reference
Transport of extracellular vesicles across the blood–brain barrier: brain pharmacokinetics and effects of inflammation
10.3390/ijms21124407 · 2020 · External reference
10.1159/isbn.978-3-318-07087-3
10.1159/isbn.978-3-318-07087-3 · 2022 · External reference
Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021 · External reference
pH-sensitive biomimetic nanosystem based on large-pore mesoporous organosilica coated with hyaluronidase
10.1021/acsami.3c06909 · 2023 · External reference
Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery
10.1016/j.ejpb.2024.114474 · 2024 · External reference
Depolymerization of hyaluronan by PEGPH20 improves nanoparticle tumor penetration in a genetically engineered mouse model of pancreatic cancer
10.2217/nnm-2020-0433 · 2021 · External reference
Intranasal delivery of cells to the brain
10.1016/j.ejcb.2009.02.001 · 2009 · External reference
Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection
10.1177/1078155218817819 · 2019 · External reference
Gene therapy comes of age
10.1126/science.aan4672 · 2018 · External reference
Unlocking the power of exosomes for crossing biological barriers in drug delivery
10.3390/pharmaceutics13010122 · 2021 · External reference
Unresolved reference
2018 · External reference
Hyaluronidase: structure, mechanism of action, diseases and therapeutic applications
10.1186/s43556-025-00299-y · 2025 · External reference
Hyaluronidase modulates inflammatory response and accelerates the cutaneous wound healing
10.1371/journal.pone.0112297 · 2014 · External reference
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration
10.1517/17425247.4.4.427 · 2007 · External reference
Gene therapy
10.1056/nejmra1706910 · 2019 · External reference
Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer
10.1158/1078-0432.ccr-15-2010 · 2016 · External reference
Unique multipotent cells in adult human mesenchymal cell populations
10.1073/pnas.0911647107 · 2010 · External reference
Hyaluronidase caveats in treating filler complications
10.1097/dss.0000000000000555 · 2015 · External reference
Rapid and widespread distribution of intranasal small extracellular vesicles to the central nervous system
10.3390/pharmaceutics15112574 · 2023 · External reference
Immunogenicity of PH20 hyaluronidase in subcutaneous drug administration
10.4155/tde.14.101 · 2015 · External reference
Key for crossing the BBB with nanoparticles: the rational design
10.3762/bjnano.11.72 · 2020 · External reference
Intranasally administered muse cells attenuate neurodegeneration in Parkinson's disease
10.1186/s12967-025-07401-6 · 2025 · External reference
Hyaluronan hydrates and compartmentalises the CNS/PNS extracellular matrix
10.1111/jnc.15915 · 2023 · External reference
The safety of recombinant human hyaluronidase PH20 in nonclinical models: an overview of toxicology, pharmacology, and impact of anti-PH20 antibodies
10.1016/j.jconrel.2024.07.062 · 2024 · External reference
Pooled safety analysis of subcutaneous trastuzumab with hyaluronidase
10.1080/14740338.2016.1202100 · 2016 · External reference
Ultrasound-guided hyaluronidase injection in managing hyaluronic acid filler-related complications
10.1097/dss.0000000000002345 · 2020 · External reference
HYLENEX recombinant (hyaluronidase human injection)
2005 · External reference
Unresolved reference
2017 · External reference
Intranasal adeno-associated virus mediated gene delivery to the central nervous system
10.3389/fnmol.2017.00226 · 2017 · External reference
Clinical applications of hyaluronidase
10.1007/978-981-13-7709-9_12 · 2019 · External reference
Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches
10.1002/jev2.12404 · 2024 · External reference
The extracellular matrix and perineuronal nets in memory
10.1038/s41380-022-01634-3 · 2022 · External reference
Comparison of subcutaneous and intravenous administration of trastuzumab
10.1177/0091270012436560 · 2013 · External reference
Recent advances in nose-to-brain gene delivery for central nervous system disorders
10.3390/pharmaceutics17020234 · 2025 · External reference
Formulation and CMC considerations for combination products in gene therapy
10.1016/j.omtm.2023.03.009 · 2023 · External reference
Small extracellular vesicles facilitate stroke recovery through enhanced perivascular delivery after intranasal administration
10.1016/j.jconrel.2023.11.015 · 2024 · External reference
Hyaluronic acid-based hydrogels as exosome delivery systems in bone regeneration
10.3389/fmats.2023.1192257 · 2023 · External reference
